With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the initial promise it saw with its BTK inhibitor Jaypirca (pirtobrutinib). Just ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results